Clinical Trial Update: Global Prevalence of ATTR-CM in Participants With HFpEF [NA]

View source ↗

Summary

Pfizer-sponsored clinical trial evaluating how common transthyretin amyloid cardiomyopathy is among people with heart failure with preserved ejection fraction h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction
• Transthyretin Amyloid Cardiomyopathy

Snippet

Sponsor: Pfizer | Conditions: Transthyretin Amyloid Cardiomyopathy, Heart Failure With Preserved Ejection Fraction | NA | Status: TERMINATED | Results posted: 2024-07-19